kaltinaitis santos

Mr. kaltinaitis santos

Universidade de Mogi das Cruzes

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FHFelipe Henriques
Felipe Henriques
MLMagno A. Lopes
Magno A. Lopes
FFFelipe O. Franco
Felipe O. Franco
PKPamela Knobl
Pamela Knobl
KSkaltinaitis santos
kaltinaitis santos
MJMiguel Luiz Batista Jr.
Miguel Luiz Batista Jr.
Cancer-induced cachexia, characterized by systemic inflammation, body weight loss, adipose tissue (AT) remodeling and muscle wasting, is a malignant metabolic syndrome with undefined etiology. Here, we show that both genetic ablation and pharmacological inhibition of TLR4 were able to attenuate the main clinical markers of cachexia in mice bearing Lewis lung carcinoma (LLC). AT remodelling was not found in LLC tumor-bearing (TB) TLR4−/−mice due to reduced macrophage infiltration and adipocyte atrophy. TLR4−/−mice were also resistant to cold-induced browning of subcutaneous AT (scAT). Importantly, pharmacological inhibition of TLR4 (Atorvastatin) reproduced the main protective effect against AT remodeling found in TLR4−/−TB mice. Moreover, the treatment was effective in prolonging survival and attenuating tumor mass growth when compared to non-treated-TB animals. Furthermore, tumor-induced elevation of circulating pro-inflammatory cytokines was similarly abolished in both genetic ablation and pharmacological inhibition of TLR4. These data suggest that TLR4 is a critical mediator and a promising target for novel anti-cachexia therapies.

30 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DJDaniela Jabes
Daniela Jabes
YMYara Natércia Lima Faustino de Maria
Yara Natércia Lima Faustino de Maria
David Aciole BarbosaDavid Aciole Barbosa
David Aciole Barbosa
KSkaltinaitis santos
kaltinaitis santos
LCLucas Carvalho
Lucas Carvalho
LNLuiz Nunes
Luiz Nunes
Cachexia (CC) is a devastating metabolic syndrome associated with a series of underlying diseases that greatly affects life quality and expectancy among cancer patients. Studies involving mouse models, in which CC was induced through inoculation with tumor cells, originally suggested the existence of a direct correlation between the development of this syndrome and changes in the relative proportions of several bacterial groups present in the digestive tract. However, these analyses have focus solely on the characterization of bacterial dysbiosis, ignoring the possible existence of changes in the relative populations of fungi, during the development of CC. Thus, the present study sought to expand such analyses, by characterizing changes that occur in the gut fungal population ( mycobiota ) of mice, during the development of cancer-induced cachexia. Our results confirm that cachectic animals display significant differences in their gut mycobiota , when compared to healthy controls. Moreover, identification of dysbiotic fungi showed remarkable consistency across successive levels of taxonomic hierarchy. Many of these fungi have also been associated with dysbioses observed in a series of gut inflammatory diseases, such as obesity, Colorectal Cancer (CRC), Myalgic Encephalomyelitis (ME) and Inflammatory Bowel Disease (IBD). Nonetheless, the CC-associated dysbiosis seems to be unique, presenting features observed in both obesity (reduced proportion of Mucoromycota ) and CRC/ME/IBD (increased proportions of Sordariomycetes, Saccharomycetaceae and Malassezia ). One species of Mucoromycota ( Rhyzopus oryzae ) stands out as a promising probiotic candidate in adjuvant therapies, aimed at treating and/or preventing the development of CC.

18 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KSkaltinaitis santos
kaltinaitis santos
PKPamela Knobl
Pamela Knobl
FHFelipe Henriques
Felipe Henriques
MLMagno A. Lopes
Magno A. Lopes
FFFelipe O. Franco
Felipe O. Franco
MJMiguel Luiz Batista Jr.
Miguel Luiz Batista Jr.
In cancer associated cachexia (CAC), white adipose tissue undergoes morphofunctional and inflammatory changes that lead to tissue dysfunction and remodeling. In addition to metabolic changes in white adipose tissues (WAT), adipose tissue atrophy has been implicated in several clinical complications and poor prognoses associated with cachexia. Adipocyte atrophy may be associated with increased beige remodeling in human CAC as evidenced by the “beige remodeling” observed in preclinical models of CAC. Even though beige remodeling is associated with CAC-induced WAT dysfunction, there are still some open questions regarding their cellular origins. In this study, we investigated the development of beige remodeling in CAC from a broader perspective. In addition, we used a grading system to identify the scAT as being affected by mice weight loss early and intensely. Using different in vitro and ex-vivo techniques, we demonstrated that Lewis LLC1 cells can induce a switch from white to beige adipocytes, which is specific to this type of tumor cell. During the more advanced stages of CAC, beige adipocytes are mainly formed from the transdifferentiation of cells. According to our results, humanizing the CAC classification system is an efficient approach to defining the onset of the syndrome in a more homogeneous manner. Pathological beige remodeling occurred early in the disease course and exhibited phenotypic characteristics specific to LLC cells’ secretomes. Developing therapeutic strategies that recruit beige adipocytes in vivo may be better guided by an understanding of the cellular origins of beige adipocytes emitted by CAC.